TY - JOUR
T1 - Dry powder platform for pulmonary drug delivery
AU - Daniher, Derek Ivan
AU - Zhu, Jesse
N1 - Funding Information:
The authors thank Ying Ma of the Particle Technology Research Centre, London, Ontario, Canada, for her advice and encouragement while writing this paper. Also, we gratefully acknowledge the National Science and Engineering Research Council of Canada (NSERC) for funding.
PY - 2008/8
Y1 - 2008/8
N2 - The phenomenon of particle interaction involved in pulmonary drug delivery belongs to a wide variety of disciplines of particle technology, in particular, fluidization. This paper reviews the basic concepts of pulmonary drug delivery with references to fluidization research, in particular, studies on Geldart group C powders. Dry powder inhaler device-formulation combination has been shown to be an effective method for delivering drugs to the lung for treatment of asthma, chronic obstructive pulmonary disease and cystic fibrosis. Even with advanced designs, however, delivery efficiency is still poor mainly due to powder dispersion problems which cause poor lung deposition and high dose variability. Drug particles used in current inhalers must be 1-5 μm in diameter for effective deposition in small-diameter airways and alveoli. These powders are very cohesive, have poor flowability, and are difficult to disperse into aerosol due to cohesion arising from van der Waals attraction. These problems are well known in fluidization research, much of which is highly relevant to pulmonary drug delivery.
AB - The phenomenon of particle interaction involved in pulmonary drug delivery belongs to a wide variety of disciplines of particle technology, in particular, fluidization. This paper reviews the basic concepts of pulmonary drug delivery with references to fluidization research, in particular, studies on Geldart group C powders. Dry powder inhaler device-formulation combination has been shown to be an effective method for delivering drugs to the lung for treatment of asthma, chronic obstructive pulmonary disease and cystic fibrosis. Even with advanced designs, however, delivery efficiency is still poor mainly due to powder dispersion problems which cause poor lung deposition and high dose variability. Drug particles used in current inhalers must be 1-5 μm in diameter for effective deposition in small-diameter airways and alveoli. These powders are very cohesive, have poor flowability, and are difficult to disperse into aerosol due to cohesion arising from van der Waals attraction. These problems are well known in fluidization research, much of which is highly relevant to pulmonary drug delivery.
KW - Aerosol
KW - Carrier particle
KW - Dry powder inhaler
KW - Fluidization
KW - Interparticle forces
KW - Pulmonary drug delivery
UR - http://www.scopus.com/inward/record.url?scp=48049116416&partnerID=8YFLogxK
U2 - 10.1016/j.partic.2008.04.004
DO - 10.1016/j.partic.2008.04.004
M3 - Review article
AN - SCOPUS:48049116416
SN - 1674-2001
VL - 6
SP - 225
EP - 238
JO - Particuology
JF - Particuology
IS - 4
ER -